LSI's Medtech Startup Tracker is focused exclusively on covering the privately-held innovators changing the medical device landscape.
The third week of March saw significant deals occur for medtech startups. An estimated $200M in funding was raised in the third week of March across seven deals. Here are some of the top deals tracked:
Start a Free Trial to Medtech Startup Tracker Today
Top Deals – Medtech Fundraising Transactions for the Week
|
Company |
Type |
Amount Raised |
Round |
|
|
AI-powered stroke care system |
$71,000,000 |
Series C |
|
|
Smart insulin delivery system |
$57,000,000 |
Series A |
|
|
Cloud-based diabetes management platform |
$30,000,000 |
Series D |
Top deals for the week are based on publicly available information. At this time of this article’s publication, new deals for the week may have been announced.
LSI's Medtech Startup Tracker is focused exclusively on covering the privately-held innovators changing the medical device landscape. Here are some of the interesting startups we’ve recently profiled:
MMI – teleoperated robotic microsurgeryThe company, also known as Medical Microinstruments, develops and commercializes the Symani microsurgery system. The Symani system is a teleoperated using proprietary NanoWrist microinstruments which reduce tremors and scale motion by a magnitude of 7-20x. MMI’s robotic platform is intended for open surgery procedures, such as lymphatic surgery, peripheral nerve repair, and microsurgical vessel repair. To-date the company has raised an estimated $24M in capital. Top competitors in the robotic surgery market include Intuitive Surgical, Medtronic, and Stryker.
MMI is a presenting company at Life Science Intelligence’s 2021 Emerging Medtech Summit.
Reperio raises $6M to support growth of its health monitoring platform
Funds from the round will be used to support and accelerate growth of its home health monitoring system. The Reperio system utilizes an FDA-approved biosensor that pairs with an individuals smartphone to offer a broad range of diagnostic screening capabilities from the convenience of the user’s home. The company is focused on developing and commercializing their platform for use by employers that want to promote wellness screening and improve the lifestyles of their employees. Beyond the employer market, Reperio intends to commercialize their system to retire facilities, nutritionists, fitness instructors, and health plans. Athenahealth, GE Healthcare, and Omron are some of the key strategics operating in this market.
HDL Therapeutics is reversing coronary atherosclerosis with lipid modifying therapy
Homozygous Familial Hypercholesterolemia (HoFH) is a rare genetic disorder that is characterized by abnormally high levels of LDL cholesterol (i.e. bad cholesterol) in the blood. HDL Therapeutics has developed the PDS-2 system, a novel biotechnology device, to increase the levels of pre-beta HDL particles and treat patients with HoFH. The PDS-2 system uses a sample of a patient’s blood plasma and increases the sample’s levels of pre-beta HDL particles. The plasma is then reinfused into the patient, which causes the pre-beta HDL particles to remove bad lipids from the patient’s vessel walls and reduce harmful plaque formation. In March 2021, HDL Therapeutics raised approximately $3.4M in financing from a Series E round. To-date, the company has raised an estimated $10.8M in funding.
Catheter Precision – noninvasive 3D arrhythmia localization
The company’s FDA-cleared VIVO system consists of a 3D camera to create a 3D rendering of a patient’s heart using previously acquired image of the patient’s chest, 12-lead ECG, and proprietary software. Electrical signals acquired by the system create a color-coded image that is superimposed onto the 3D rendering to help physicians identify regions of the heart requiring cardiac ablation. The technology is intended to facilitate pre-procedure planning for patients with ventricular arrhythmias. Bionsense Webster, Abbott, and Medtronic are key strategics in the cardiac mapping and ablation market.
Catheter Precision is a presenting company at Life Science Intelligence’s 2021 Emerging Medtech Summit.
Bigfoot Biomedical raises $57M in Debt/Equity Financing
Bigfoot Biomedical is developing a holistic approach to insulin management. The company’s Unity Diabetes Management System is composed of a smart insulin delivery pen, automated infusion pump, and smartphone application powered by machine learning. Through this holistic platform, the company aims to significantly reduce the cognitive, emotional, and financial burden of diabetes management. With the completion of this recent financing round, the company has raised an estimated $205M to-date. Key competitors in the diabetes management market include Dexcom, Insulet, and Tandem Diabetes Care.
Vascular Therapies is developing a bioresorbable implant to address unmet needs in vascular access
The company’s bioresorbable collagen implant is being investigated for use in patients with newly formed AV fistulas that are receiving hemodialysis. The implant elutes the drug sirolimus to reduce cellular proliferation and maintain vessel patency as the fistula matures. The device is currently being evaluated in a Phase 3 clinical trial for hemodialysis fistulas. In addition to this Phase 3 study, the device has been investigated in clinical studies for use with AV grafts and peripheral arterial bypass grafts. Vascular Therapies has raised an estimated $54.9M in funding to-date. BD, Terumo, and W.L Gore are some of the key strategics in the hemodialysis market.
Vascular Therapies is a presenting company at Life Science Intelligence’s 2021 Emerging Medtech Summit.
Learn about the hottest venture funded startups developing innovative medical technologies using Life Science Intelligence’s Medtech Startup Tracker.
Schedule an exploratory call
Request Info© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
